NCT03703908View on ClinicalTrials.gov

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

June 24, 2020

Study Completion Date

June 24, 2020

Conditions
Focal Segmental Glomerulosclerosis
Interventions
DRUG

CCX140-B

Orally administered tablet

Trial Locations (5)

55414

University of Minnesota, Minneapolis

71101

Northwest Louisiana Nephrology, Shreveport

84115

Utah Kidney Research Institute, Salt Lake City

90502

Los Angeles Biomedical Research Institute, Torrance

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY